The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and ...

Japanese pharmaceutical company Eisai Co and U.S. firm Biogen Inc said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease ...

This dual-modality technique could enable the detection of functional changes in amyloidosis and offer a better method for tracking disease progression & treatment response over time. "This ...

Neuraly and Enigma Biomedical USA announce a Research License and Commercialization Option Agreement for PET Imaging Biomarker, PMI04 ...

This dual-modality technique could enable the detection of functional changes in amyloidosis and offer a better method for tracking disease progression & treatment response over time. “This ...

Enigma’s neuroimaging biomarkers provide Pharma and Academic researchers with state-of-the-art tools for enabling Disease-Modifying ... the best-in-class Tau and Amyloid PET imaging biomarkers ...

Early ATTR‐CA screening in patients with AS may improve outcomes given the availability of disease‐modifying therapy. Raising clinicians' awareness of the clinical clues associated with ATTR‐CA may ...

The diagnosis of cardiac amyloidosis can be a challenging and time-consuming process for patients, with many going years without an accurate diagnosis, and losing critical time in the process”, said ...